Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on access to Fampridine by people with multiple scleroris.

We have had no such discussions. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether medicines represent a clinical and cost-effective use of resources.

NICE was unable to recommend fampridine in its clinical guideline on managing multiple sclerosis (MS) which was originally published in 2014. However, NICE is now updating this guideline, which will include reviewing the recommendation on fampridine. NICE expects to publish its draft guidance on the management of MS for consultation in December this year, with final guidance expected on 1 June 2022.